<DOC>
	<DOC>NCT01457118</DOC>
	<brief_summary>The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102. In addition the study will evaluate the safety of continued exposure to NKTR-102, observe disease status and survival status in subjects receiving NKTR-102, and evaluate the efficacy of NKTR-102 in subjects with advanced or metastatic solid tumors.</brief_summary>
	<brief_title>An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies</brief_title>
	<detailed_description />
	<criteria>Inclusion: 1. Received prior treatment with NKTR102 2. Free of disease progression since receiving NKTR102 3. Adequate bone marrow and organ function 4. Treatment with NKTR102 in the extension study to begin within 8 weeks after receipt of their of last dose of NKTR102 5. Agree to use adequate contraception Exclusion: 1. Treatment with other anticancer therapy between the last dose of NKTR102 in the prior study and before first dose of NKTR102 in the extension study 2. A toxicity that requires a 3rd dose reduction after taking NKTR102 or are scheduled to receive a dose &lt; 70 mg/m2 upon entry into this study 3. Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Open Label multicenter extension study advanced solid tumors</keyword>
</DOC>